Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Comparative effects of a dipeptidyl peptidase-4 inhibitor and of NPH insulin on peripheral nerve conduction of patients with type 2 diabetes

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1Email author
Diabetology & Metabolic Syndrome20157 (Suppl 1) :A59

https://doi.org/10.1186/1758-5996-7-S1-A59

  • Published:

Keywords

  • Metformin
  • Diabetic Neuropathy
  • Sitagliptin
  • Peripheral Diabetic Neuropathy
  • Glyburide

Background

Studies in animals have suggested that the glucagon-like peptide-1 hormone (GLP-1) has neurotrophic properties that were independent of those related to the improvement of glucose control. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase GLP-1 levels and are effective in improving metabolic parameters in patients with type 2 diabetes mellitus (T2D) but little is known about its effects on neurological disorders, including peripheral diabetic neuropathy.

Objective

To assess the effects of the DPP-4 inhibitor sitagliptin on nerve conduction and their independence on glucose control.

Materials and methods

Thirty patients with T2D (39-66 yrs.), diabetes duration of 10.9 yrs., inadequately controlled with metformin plus glyburide (HbA1c between 6.9 to 9.1%) were randomized to receive sitagliptin (n=16) or bedtime NPH insulin (n=14) as add-on therapy. HbA1c, fasting blood glucose, body weight and electroneurography were determined before and after 1 year of treatment.

Results

HbA1c levels decreased both in the sitagliptin (8.01±0.57 x 7.36±1.96, p=0.04) and NPH group (8.11±0.64 x 7.34±0, 68, p <0.001). The weight of patients remained stable. There was no change in sensory and motor nerve conduction parameters in the 2 groups.

Conclusions

Sitagliptin and bedtime NPH insulin were effective in reducing HbA1c, after 1 year of treatment. The improvement of glucose control, the use of sitagliptin or bedtime NPH insulin did not lead to improvement in peripheral nerve conduction in patients with long-standing type 2 diabetes.

Authors’ Affiliations

(1)
FMUSP, São Paulo, Brazil

Copyright

© da Silva et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement